Aircraft exports from the US: A Vedder Price analysis - Corporate Jet Investor corporatejetinvestor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from corporatejetinvestor.com Daily Mail and Mail on Sunday newspapers.
There were 63 professional, scientific and technical services businesses in ZIP code 85737 that employed fewer than five people in 2017, according to County Business Patterns (CBP) statistics provided by the United States Census Bureau.
CBP data indicates that no other industry had more establishments with fewer than five employees in ZIP code 85737 than professional, scientific and technical services businesses.
The following table shows the top 10 industries of total establishments with fewer than five employees in ZIP code 85737 in 2017.
Top 10 Industries with fewer than five employees in ZIP code 85737 (2017)
Industry
India is stepping back from importing ferrous scrap and aiming to become a more self-sufficient steelmaker. But what issues led to this change of tactics and how will it affect global scrap trade flows? Fastmarkets investigates.
The global scrap market is under pressure from a variety of challenging conditions - from a Covid-19-related shortage of shipping containers, to port delays and rising port and freight charges.
This combination of factors has resulted in one key scrap market looking to move away from imported material and India s steel industry is now aiming to meet its needs using domestic raw materials under prime minister Narendra Modi s ‘Atmanirbhar Bharat’ policy - which translates as ‘self-reliant India’.
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million
RP Management, LLCApril 8, 2021 GMT
Dicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments
NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. OXLUMO, which has been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of primary hyperoxaluria (PH) type 1, is marketed by Alnylam Pharmaceuticals, Inc. (“Alnylam”).